Warning: The NCBI web site requires JavaScript to function. more...
Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project.
Svärd A, Kastbom A, Reckner-Olsson A, Skogh T.
Arthritis Res Ther. 2008;10(4):R75. Epub 2008 Jul 4.
Related citations
A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
Svärd A, Kastbom A, Söderlin MK, Reckner-Olsson Å, Skogh T.
J Rheumatol. 2011 Jul;38(7):1265-72. Epub 2011 Apr 1.
Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.
Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapää-Dahlqvist S.
Ann Rheum Dis. 2006 Apr;65(4):453-8. Epub 2005 Sep 21.
Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).
Kastbom A, Strandberg G, Lindroos A, Skogh T.
Ann Rheum Dis. 2004 Sep;63(9):1085-9.
Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
Greiner A, Plischke H, Kellner H, Gruber R.
Ann N Y Acad Sci. 2005 Jun;1050:295-303.
Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J.
Arthritis Rheum. 2008 Jan;58(1):36-45.
A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis.
dos Anjos LM, Pereira IA, d 'Orsi E, Seaman AP, Burlingame RW, Morato EF.
Clin Rheumatol. 2009 Feb;28(2):153-8. Epub 2008 Sep 16.
Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
Caspi D, Anouk M, Golan I, Paran D, Kaufman I, Wigler I, Levartovsky D, Litinsky I, Elkayam O.
Arthritis Rheum. 2006 Feb 15;55(1):53-6.
High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P, van der Heijde D, Landewé R, Kvien TK.
Ann Rheum Dis. 2008 Feb;67(2):212-7. Epub 2007 May 25.
Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H, Sugii S, Ozawa Y, Tohma S.
J Rheumatol. 2006 Dec;33(12):2390-7. Epub 2006 Aug 15.
Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.
Agrawal S, Misra R, Aggarwal A.
Clin Rheumatol. 2007 Feb;26(2):201-4. Epub 2006 Mar 30.
Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.
Lakos G, Soós L, Fekete A, Szabó Z, Zeher M, Horváth IF, Dankó K, Kapitány A, Gyetvai A, Szegedi G, Szekanecz Z.
Clin Exp Rheumatol. 2008 Mar-Apr;26(2):253-60.
The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis.
Shovman O, Gilburd B, Zandman-Goddard G, Sherer Y, Orbach H, Gerli R, Shoenfeld Y.
Clin Dev Immunol. 2005 Sep;12(3):197-202.
Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR.
J Rheumatol. 2008 Jun;35(6):1002-8. Epub 2008 Apr 1.
Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis.
Vencovský J, Machácek S, Sedová L, Kafková J, Gatterová J, Pesáková V, Růzicková S.
Ann Rheum Dis. 2003 May;62(5):427-30.
Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K.
Ann Rheum Dis. 2004 Sep;63(9):1079-84.
Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).
Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B; BARFOT Study Group.
Ann Rheum Dis. 2004 Sep;63(9):1090-5.
Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis.
Kaltenhäuser S, Pierer M, Arnold S, Kamprad M, Baerwald C, Häntzschel H, Wagner U.
Rheumatology (Oxford). 2007 Jan;46(1):100-4. Epub 2006 May 25.
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ.
Arthritis Rheum. 2003 Oct;48(10):2741-9.
Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.
van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, van Venrooij WJ, Verweij CL, Toes RE, de Vries RR.
Arthritis Rheum. 2004 Jul;50(7):2113-21.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on